pharmaceuticals

Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.

Drug companies’ political committees have largely donated to Republican presidential campaigns since 1990, but that trend has noticeably reversed come the 2020 election cycle, according to a new report from the Center for Responsive Politics.